A timely convergence of many factors, including gene-editing technologies, machine learning, nanomedicine, and artificial intelligence, is making it tremendously exciting to be an engineer at the interface of medicine. This is further fueled by the recognition that we need bold strategies to tackle health care challenges across the world including ways to prevent autism and Alzheimer's, making medicines economical, and speeding up the process of translation. Brining perspectives from across the spectrum of stakeholders is critical to speeding up translation. Engineers are wellpositioned to be an enabling community in this regard. Recognizing this opportunity, the American Institute of Chemical Engineers (AIChE) and In many ways, the articles in both of the two conference special issues, and the BTM conference highlighted the rich variety and depth of perspectives bioengineers can bring to important health issues, through their collaborations with physicians, regulators, and investors. We may be at the tipping point where such perspectives can accelerate translation of discoveries, human impacting health meaningfully.

